Virtual Library
Start Your Search
Ozlem Ercelep
Author of
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-33 - EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis (ID 12510)
12:00 - 13:30 | Author(s): Ozlem Ercelep
- Abstract
Background
There has been important developments in NSCLC since the understanding of molecular pathways. The aim of the study is to find the EGFR mutation frequency and its correlation to survival and clinicopathological features. We reported our data in this subject three years ago. We aim to resubmit our updated data.
a9ded1e5ce5d75814730bb4caaf49419 Method
In this multicenter study, 1352 NSCLC (adenocarcinoma) patients were included retrospectively to find out the EGFR mutation status with age, sex, performance status, histopathological diagnosis, smoking status and stage. Survival correlates were determined. The aim of the study was to find out the EGFR mutation status with all of the features in the database.
4c3880bb027f159e801041b1021e88e8 Result
The median age was 59 (24-87) years. Median follow-up time was 14 (2-117) months. 26,2 % were female. 85,2% were stage IIIB-IV and 86 % was adenocarcinoma. EGFR mutation frequency was 22,3 % including exon 19 (63,0%). There was no correlation between mutational status and age, performance status, and stage at diagnosis (p>0,05). However, there was a correlation between gender and, smoking.. (p= 0.000 and 0,000. respectively). The frequency of mutation in female patients was more pronounced in non-smokers/ex-smokers. In the group that can perform survival analysis (827 pts), median progression-free survival was 9 months and overall survival was 20 months. The overall survival was 27 (SE:5; 95% CI 17-36) months in EGFR positive cases whereas 19 (SE:1; 95% CI 16-21) months in EGFR negative cases (p=0,008). The multivariate analysis showed good performance status, early stage disease and presence of EGFR mutation as a prognostic factor (p<0,05).
8eea62084ca7e541d918e823422bd82e Conclusion
Our investigation shows that the EGFR mutation rate in our patient population with adenocarcinoma of the lung was higher than in Western countries population and was lower than the East Asian population. The determination of EGFR mutation will lead the pathway for a better treatment outcome and individualized therapy.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.16-48 - Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer? (ID 12355)
12:00 - 13:30 | Author(s): Ozlem Ercelep
- Abstract
Background
Positron emission tomography-computed tomography (PET / CT) is currently recommended to rule out metastatic disease in non-small cell lung cancer (NSCLC), even in early stage patients. In this study, our aim is to evaluate the effect of maximum value of standardized uptake values (SUVmax) of primary tumor in PET/CT before surgery on relapse in operable NSCLC.
Data from 191 operable stage I-III NSCLC patients who had preoperative PET/CT was retrospectively analyzed between 2006-2018. Demografic and clinicopathologic findings were analyzed.Patients were staged according to TNM 8th edition. ROC curve analysis was performed to determine the ideal cut-off value of preoperative SUV max to predict relapse. The findings were analyzed using SPSS.
At the time of diagnosis, median age was 62 years (39-82) and 84% of patients were male. Eighty-nine percent of our patients were smokers and smoking rate in males was 98%. Most common pathologic subtype was adenocarcinoma (Table 1). Mean follow-up duration was 35 months (1-128 months). Fourty-seven percent recurred and median progression free survival time (PFS) was 45 months (29-60 months). Median overall survival (OS) was 80 months.The ideal cut-off value of preoperative SUVmax that predicted relapse was 10.75 in the ROC analysis [AUC: 0,58 (0,50-0,66) p<0,05 with a sensitivity of 65%, and specificity of 57%]. Median PFS was 89 months in patients with preoperative SUVmax ≤ 10.75, and 34 months in patients with SUVmax > 10.75 (HR= 1.69; 95% CI 1.09-2.61; P =0.01).
Table 1 Demographic and clinicopathological findings
Gender
Male
160 (%84)
Female
31 (%16)
Smoking
Yes
171(%89)
No
20 (%11)
Stage
Stage 1
(n=51)
Stage 1A1-A3
33 (%17)
Stage 1B
18 ( %10)
Stage 2
(n=78)
Stage 2A
17 ( %8)
Stage 2B
61( %32)
Stage 3
(n=62)
Stage 3A
53(%28)
Stage 3B
9 (%5)
Pathology Subtype
Adenocarcinoma
98 (%51)
Squamous cell carcinoma
81 (%42)
Others
12 (%7)
Adjuvant treatment (n=123)
Stage 1
5 (%4)
Stage 2
65(%53)
Stage 3
53 (%43)
Recurrences
Yes
90 (%47)
No
101 (%53)
Recurrence patterns
Local
15 (16 %)
Systemic
75 (84 %)
Status
Alive
131 (%69)
Ex
60 (%31)
Approximately 30% of NSCLC patients are diagnosed at early stage. Although surgery is curative treatment in early stage, recurrences are common. Preoperative SUV(max) of primary tumor in PET/CT might be a predictor of postoperative relapse for operated NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53